Institutional analyst consensus in the Vertex stock price forecast now supports an “Overweight” rating, bolstered by expanding therapeutic pipeline into non-cystic fibrosis indications. Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have forecasts for Vertex Pharmaceuticals going out to 2027, and you can see them free on our platform here. Vertex will now focus on diabetic peripheral neuropathy (DPN) as its main target for chronic pain treatment after the FDA said it doesn’t currently support a broader label for peripheral neuropathic pain (PNP). A risk-adjusted Vertex stock price forecast suggests volatility may spike around upcoming FDA decisions, making protective stop orders a smart tactic for active traders.